Home Companies Catalysts Deep Dives
BIC/LEN bictegravir/lenacapavir PHASE3
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaInfectious Disease
Peak Sales Est$5000M
Companies
GILD (ORIGINATOR)100%
Mechanism: Integrase strand transfer inhibitor (INSTI)
Expert: Inhibits HIV-1 integrase, preventing viral DNA integration into host genome.
Everyday: Blocks HIV from inserting its genetic material into human cells.
Targets: ["HIV INTEGRASE"]
Programs (1)
IndicationStageKey StudyRegional Status
HIV-1 treatmentPHASE3ARTISTRY-1/2—
Upcoming Catalysts (1)
BIC/LEN - HIV Treatment - FDA Filing H1 2026
Notes
Once-daily oral HIV treatment combining INSTI + capsid inhibitor. ARTISTRY-1/2 Phase 3 positive (Nov 2025). Filing planned 2026.
Data from Supabase · Updated 2026-03-24